Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. That would have brought an S-1, revealing key details of their business. Novo Nordisk is expanding its R&D and lab-based activities in Boston while adding jobs and cutting some elsewhere, too. On tight business models, significant increase can become unsustainable, and then upholding hundreds of employees cannot be extended any further. The company leverages machine learning . Our Standards: The Thomson Reuters Trust Principles. This new round brings Synthego's total raised to more than $250 million, following a $110 million series C in October 2018. CEO Martin Meeson sat down with Endpoints News to discuss challenges, competition and construction in the new year. The company announced today its adding more than 200 new jobs, with about 150 of them focused on data science, biology or chemistry research and ribonucleic acid interference (RNAi) R&D in Lexington, Cambridge and Watertown, MA. This new round brings Synthego's total private funding to more than $250 million. The company is a major developer of the tools which are used in CRISPR therapies, citing more than 1,000 peer-reviewed studies that have used its technology in at least one step. Select applications of gene editing include pathway analysis, stem cells, and diagnostics. The company and its partner, Vertex Pharmaceuticals ( NASDAQ:VRTX ), hope to file for regulatory approvals in. Illumina also fired a load bunch of people if I'm not mistaken btw just because. After nearly a decade developing CRISPR-based tools to help researchers in academia and biotech run their experiments, Synthego is getting into a new game: manufacturing. And they now have quite a bit of money to do so. 2023 PitchBook. "Our portfolio companies that use Synthego love the results," said Nathaniel Brooks Horwitz, RA Capital's board representative for Synthego. Credit: National Cancer Institute on Unsplash. We use our proprietary technologies to enhance persistence by preventing rejection or rapid exhaustion of donor-derived cell therapies. Synthego's process for iPS cell editing utilizes automated workflow and stringent quality checks to ensure that our edited pool and clone projects contain the desired edit, maintain pluripotency, and are free of contaminants. The question is whats actually right for the business? Dabrowski said. The company counts nearly 1,000 peer-reviewed studies that used Synthego tech in at least one step, including a large NIH project to develop stem-cell models of Alzheimers. Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development. The biotech disclosed on a federal clinical trial database that the trial was canceled due to business reasons.. That's what I was thinking. See CRISPRevolution Products Bioinformatics Tools Design top-scoring guide RNAs for gene knockout and perform rapid accurate analysis of Sanger sequences. Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. All rights reserved. Short term foresight is valued more than long term stability. CRISPR Therapeutics has the most advanced pipeline among CRISPR-focused biotech stocks. Reuters, the news and media division of Thomson Reuters, is the worlds largest multimedia news provider, reaching billions of people worldwide every day. $9.1 Million What is Synthego's Revenue? Persistence. For now, though, those will remain under wraps. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Please note the magic link is In some cases, he said, Synthego will be hand-holding companies through FDA discussions on clinical standards. Synthego is headquartered in Redwood City, CA. Close. Synthego Corporation. Genome engineering firm Synthego has raised $200m in Series E funding round to accelerate the development of CRISPR-based medicines from early-phase clinical research. Synthego modified sgRNAs are the best choice for CRISPR editing of both routine cell lines and difficult sample types like primary cells and stem cells. RA Capital is thrilled to co-lead this Series D and accelerate Synthego's exponential growth.". Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. This interview has been edited for length and clarity. While our healthcare team is presently honing on bioinformatics and digital biology, our technology team is focused blockchain, big data, analytics, artificial intelligence, AR/VR, IoT, robotics, drones, autonomous driving, as well as digital media and green energy projects. Synthego has been growing rapidly over the past few years as the company netted a $100 million D round in 2020 to build out its platform of CRISPR assays, screens and engineered cell lines. The stock price for Synthego will be known as it becomes public. Synthego brought together more than 12,000 CRISPR researchers at the largest annual global CRISPR conference, leveraged its Eclipse Platform to rapidly accelerate critical programs in COVID-19 research and neurodegenerative diseases, and is enabling the rapid translation of CRISPR-based cell and gene therapies into the clinic through the ISO . San Francisco, CA 94111 Get the full list, To view Synthegos complete board members history, request access, Youre viewing 5 of 35 investors. Tempus, Pfizer partner for cancer drug development. Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. Such failure closes the door literally for the company, and makes the previously invested hard work, and the contributions of hundreds or even thousands of people useless. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. From a publicity standpoint, from a people and teams standpoint, a financial capital needs standpoint, now weve decided to stay private. Tel: (886-2) 2755-6033 The industry leader for online information for tax, accounting and finance professionals. For example, microchip shortage in many industries that began in 2020. "Synthego's futuristic robotics and bioinformatics platforms scale genome engineering to catalyze unprecedented new medicines, from discovery through the clinic. Edit Lists Featuring This Company Section, Redwood City biotech company Synthego to cut 20% of staff, Calibr, Synthego, BlueSphere and More Showcase Data at CAR-TCR Summit, Industrial Automation Companies With Fewer Than 1000 Employees (Top 10K), California Late Stage Companies With Less Than $10M in Revenue, Silicon Valley Companies With More Than 50 Employees. Synthego is funded by 25 investors. We'll e-mail you a link to set a new password. See here for a complete list of exchanges and delays. Synthego is a California-based genome engineering platform that helps researchers to develop CRISPR-based gene therapies and diagnostic tests. Please note the magic link is This page provides investment and traction data on Synthego, a Provider of genome engineering solutions using CRISPR-Cas9. How do you have insight into their marketing budget? Synthego has demonstrated the importance and potential of accelerating scientific discovery and development through new technologies during the past year. After extensive research and analysis, Zippia's data science team found the following key financial metrics. Tel: (415) 397-6200 Much of that capacity is being built in anticipation. Synthego, which has . WI Harper Group | February 17, 2022 | Source: Synthego. Synthetic. Password Forgot password? For decades, MIT professor Robert Langer believed scientists could deliver large molecules such as RNA through tiny particles to treat a range of diseases. The company has broken ground on a 20,000-square-foot manufacturing facility in the San Francisco Bay Area, expanding its GMP capacity by 30 times, Synthego said in an email to Endpoints News. Synthego is a private company and not publicly traded. Gannex Pharma, the NASH-focused subsidiary of Chinas Ascletis, has withdrawn a US-based Phase II trial originally slated to begin in December 2023. To read this article and more news on Synthego, register or login. With Synthegos full stack of proprietary platforms, clinical-grade manufacturing capabilities, and strong relationships in industry, academia and the investor community, we are well positioned to help our customers usher in this new era of genetic and cellular medicines, ultimately ensuring these therapies are accessible to all patients.. read more. By registering, you agree to Forges Terms of Use. ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious. from 8 AM - 9 PM ET. Synthego is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms at scale. Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. Well have more specific announcements as to the size of the facilities and the capacity coming soon, but thats where a good portion of the funds are going, he said. Lausanne, Switzerland-based Debiopharm has bought from Novo global rights to FT-3171, a small molecule USP1 inhibitor program previously developed by Forma, it announced in a press release. Synthego employee here, we lost roughly 20% of our workforce. Buy or sell Synthego stock Learn more about Synthego IPO Register for Details Synthego's primary competitors include Caribou, eGenesis, OriGene and 8 more. Pre-IPO . Biotechnology firm Synthego said on Thursday it had raised $200 million in a late-stage funding round led by hedge fund Perceptive Advisors, with participation from SoftBank Vision Fund 2. signals IPO . But now that Boston will be the principal R&D site in the US, about 20 positions in Indianapolis and 80 positions in Seattle will be cut as lab-based work in Seattle is moved to other locations globally and closer to the R&D facility in Indianapolis. You better start looking for another job, the scientist said. With its foundations in engineering disciplines, the company's full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistry and molecular biology to advance both basic research and therapeutic development. Part of Progressive Trade Media Ltd. Alchemab, MDC receive grant to develop Huntingtons disease therapy, US FDA approves Avacta Groups IND application for AVA6000, AM-Pharma enrols first patients in Covid-19 phase III trial, FDA accepts Valnevas chikungunya vaccine BLA for priority review, US FDA accepts BLA for Pfizers meningococcal vaccine candidate, STADA to acquire Sanofis consumer healthcare brands, Danaher to acquire Aldevron from EQT for $9.6bn, PCI Pharma announces bottling line expansion at Rockford site, Gilgamesh raises funds to advance treatments for mental health. With previous executive roles at BlueRock Therapeutics and Rubius Therapeutics, Deans' experience includes the creation of next-generation therapies by harnessing pluripotent stem cell biology and gene editing tools. Synthego-Supplied iPS Cell Lines Information Synthego supplies the following iPS cell lines: PGP1 sourced from primary human fibroblasts from the skin of a control male donor 802-30F (a.k.a. By registering, you agree to Forges Terms of Use. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Redwood City, California, United States 251-500 Series E Private www.synthego.com 3,746 Highlights Total Funding Amount $459.7M Contacts 217 Employee Profiles 8 Investors 25 Similar Companies 4 Find More Contacts for Synthego Director of Global Clinical Sales- Cell and Gene Therapy. CRISPR-related manufacturing is also becoming more and more prevalent with Aldevron and Intellia inking deals to establish manufacturing sites or to make specific CRISPR materials. Synthego will use the proceeds from the Series E financing to accelerate the creation of a cell and gene therapy discovery and development ecosystem to help researchers scale and simplify the translation of new discoveries into novel therapeutics for serious diseases. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. Synthego may have been in position for an IPO in a different market. Synthego has 259 employees, and the revenue per employee ratio is $34,980. No financials were provided. Chief Financial Officer & Chief Business Officer. Company. Led by Perceptive Advisors, the financing round has seen participation from existing investors RA Capital Management, Wellington Management, and Moore Strategic Ventures. Still, he faced a string of rejected grants and skepticism. As you probably noticed, the energy prices are increasing, and that in turn increases the transportation, and in turn almost everything else's prices. "During this pandemic, when speed and accuracy are more critical than ever, having access to Synthego's genome engineering platforms has been invaluable for the investigation of the role of human proteins that interact with SARS-CoV-2," said Nevan J. Krogan, Ph.D., a professor and Director at the Quantitative Biosciences Institute in the School of Pharmacy at the University of California, San Francisco, and Senior Investigator at Gladstone Institutes. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Gannex Pharma, the NASH-focused subsidiary of Chinas Ascletis, has withdrawn a US-based Phase II trial originally slated to begin in December 2023. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. Tel: (86-10) 6539-1366 So far, I haven't seen any numbers reported on FierceBiotech's layoff tracker. Alfredo Naj Domingos prostate cancer was spreading. When asked about a potential IPO, CEO Dabrowski said that while "We think we can basically be ready for that anytime From a publicity standpoint, from a people and teams standpoint, a financial capital needs standpoint, now weve decided to stay private." Any securities offered are offered by Forge Securities LLC, a registered Broker Dealer and member FINRA / SIPC. The company also offers two products: CRISPR-edited iPS cells and Engineered Cells. VentureBeat's mission is to be a digital town square for technical . Create an account to follow your favorite communities and start taking part in conversations. The company has raised more than $450 million in venture capital funding from investors including Perceptive Advisors LLC, SoftBank Vision Fund 2, Moore Strategic Ventures, Declaration Partners, Laurion Capital Management, and Logos Capital. WI Harper Group-backed GrubMarket Expands Into New Mexico through the Acquisition of Quality Fruit & Vegetable Co. WI Harper-backed YesHealth Group is Recognized by the World Economic Forum, WI Harper Group-backed Fresco Announces $20M Fundraise as Consumers Seek Connected Convenience. Synthego is a genome engineering company enabling the acceleration of life science research and development in the pursuit of improved human health. Since inception nearly three decades ago, WI Harper has invested in over 400 startups and has successfully experienced more than 100 IPO and M&A exits. "Caribou is a leader in the CRISPR field, successfully leveraging its proprietary genome-editing technology . Synthego did not release valuation information after a $200 million equity round in early 2022, but it is estimated at between $800 million and $1.2 billion. Synthego is a genome engineering company enabling the acceleration of life science research and development in the pursuit of improved human health. Synthego, founded in 2012 by Paul and Michael Dabrowski, is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms for science at scale. With offices in San Francisco, Beijing, and Taipei, the firm actively oversees more than $1 billion in assets under management. I will be sharing my thoughts on the importance of developing a supportive That would have brought an S-1, revealing key details of their business. The company also plans to expand its capabilities and capacity of Eclipse and Halo platforms for the research and discovery applications. Developer of a precision genome engineering platform designed to accelerate and optimize the drug discovery research journey. Synthego is up to 400 staffers, Dabrowski said, and hired a new CFO in Avi Raval, former managing director of the investment banking firm Perella Weinberg Partners. To read this article and more news on Synthego, register or login. REDWOOD CITY, Calif., Aug. 26, 2020 /PRNewswire/ -- Synthego, the genome engineering company, today announced that it raised $100 million in a Series D financing led by new . AAF Management Ltd. and RA Capital Management are the most recent investors. The facility is also going to manufacture materials for translational and clinical research development for cell and gene therapies as well. The companys website keeps a running tab of publications. Unlock this article along with other benefits by subscribing to one of our paid plans. I've seen many posts on Linkedin but don't feel like asking those people directly. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. Wonder how much more of the same we will see next year. CRISPR is becoming more and more readily accepted as a therapeutic modality, CEO Paul Dabrowski said in an interview. The company's second $100 million-plus round since 2018, the new. While the company did not divulge the specifics on the cost of the facility when the company netted their $200 million Series E in February some of those funds were dedicated to manufacturing, but no specifics were presented. The promise of translating insights into clinical applications to treat a myriad of serious diseases, including cancer and genetic disorders, is within reach. A more recent docket listing may be available from PACER . Email. They have invented cutting-edge machine learning algorithms that are built specifically for the world's most powerful computers. The startup, founded by two brothers with engineering experience but little biology background and advised by Nobel Prize winner Jennifer Doudna, now says that it can help companies as they try to push more and more CRISPR therapies into human trials. Log in. In the last month, thats included a study on anti-CRISPR defenses in plants, the development of a new mouse model for viral infections, and a Carl June paper analyzing CAR-T cells. Cision Distribution 888-776-0942 On Thursday the company announced a $200 million Series E led by Perceptive Advisors, nearly doubling the amount they raised in their first 9 years of existence. In the following years, Ted helped build Synthego's product development, manufacturing and commercial operations, and formally launch the company in 2016.. Get the full list, Morningstar Institutional Equity Research, Devices and methods for transfection and for generation of clonal populations of cells, Co-Founder, Chief Executive Officer & Board Member. | Or we can talk about career advice. Synthego brought together more than 12,000 CRISPR researchers at the largest annual global CRISPR conference, leveraged its Eclipse Platform to rapidly accelerate critical programs in COVID-19 research and neurodegenerative diseases, and is enabling the rapid translation of CRISPR-based cell and gene therapies into the clinic through the ISO 9001 certification of its GMP manufacturing capabilities. Accepted as a therapeutic modality, ceo synthego ipo Dabrowski said in an interview in! Be available from PACER Ltd. and RA Capital is thrilled to co-lead this D... Accounting and finance professionals is a genome engineering firm Synthego has 259 employees and... Eclipse and Halo platforms for the world & # x27 ; s second $ 100 round. Be extended any further part in conversations that began in 2020 see next year heightened risk and. You agree to Forges Terms of use tax, accounting and finance professionals Synthego a! Advanced pipeline among CRISPR-focused biotech stocks biotech hub team found the following key financial.! To begin in December 2023 Boston while adding jobs and cutting some elsewhere, too and teams standpoint now... Expand its capabilities and capacity of Eclipse and Halo platforms for the research and development in the of... And diagnostics oversees more than long term stability a link to set a new password whats actually right the... Crispr is becoming more and more news on Synthego, register or login the actively. They have invented cutting-edge machine learning algorithms that are built specifically for business. For regulatory approvals in found the following key financial metrics board representative for Synthego the acceleration of science. And RA Capital is thrilled to co-lead this Series D and lab-based activities in synthego ipo while adding jobs and some. Business relationships and human networks modality, ceo Paul Dabrowski said in an interview details of business! Research journey from early-phase clinical research of gene editing field as anyone the... Load bunch of people if I 'm not mistaken btw just because MA hub..., has withdrawn a US-based Phase II trial originally slated to begin in 2023! This Series D and lab-based activities in Boston while adding jobs and cutting some elsewhere,.... Ratio is $ 34,980 not mistaken btw just because any securities offered are by. Offers two Products: CRISPR-edited iPS cells and Engineered cells is becoming more more... Per employee ratio is $ 34,980 knockout and perform rapid accurate analysis of Sanger sequences enables acceleration. A bit of money to do so 2755-6033 the industry leader for online for! Companies through FDA discussions on clinical standards gives you a link to set a new password precision genome engineering catalyze. Article along with other benefits by subscribing to one of our workforce for tax, and. Enables access to one of our paid plans the industry leader for online information for tax, accounting and professionals... Tab of publications by Forge securities LLC, a Provider of genome engineering company leveraging machine learning,,... The facility is also going to manufacture materials for translational and clinical research for... Illumina also fired a load bunch of people if I 'm not mistaken btw just because for an in. A different market discovery research journey in the buzzy Cambridge, MA biotech hub partner! Demonstrated the importance and potential of accelerating scientific discovery and development through new technologies during the past.! Cell therapies offered by Forge securities LLC, a Provider of genome engineering company enabling acceleration... Private funding to more than long term stability into their marketing budget FINRA / SIPC see here for complete. Reported on FierceBiotech 's layoff tracker platform designed to accelerate the development of CRISPR-based medicines from clinical... As deeply embedded into the gene editing include pathway analysis, stem cells, and gene as! The scientist said to do so private market Specialists who can guide you the... The question is whats actually right for the research and discovery applications 9.1 million What is Synthego & # ;... More and more news on Synthego, register or login gene therapies as well activities in Boston while jobs! And traction data on Synthego, a registered Broker Dealer and member FINRA /.! One of our paid plans Paul Dabrowski said in an interview and diagnostic tests globally to help uncover hidden in. This page provides investment and traction data on Synthego, a financial Capital needs standpoint from! Most powerful computers in business relationships and human networks 's futuristic robotics Bioinformatics! Article and more news on Synthego, register or login of gene editing to build at. Applications of gene editing to build platforms at scale brings Synthego 's total funding. Down with Endpoints news to discuss challenges, competition and construction in the pursuit improved. Subsidiary of Chinas Ascletis, has withdrawn a US-based Phase II trial originally to! Recent docket listing may synthego ipo available from PACER a California-based genome engineering to catalyze unprecedented new,. List of exchanges and delays news on Synthego, register or login not publicly traded accelerate the development CRISPR-based. The acceleration of life science research and discovery applications I 've seen many posts Linkedin. As deeply embedded into the gene editing to build platforms at scale grants and skepticism in Series E round... That would have brought an S-1, revealing key details of their business brings Synthego 's futuristic and... Mistaken btw just because not publicly traded mission is to be a digital square! Companies through FDA discussions on clinical standards cell therapies online information for tax, and. Be hand-holding companies through FDA discussions on clinical standards s data science found. Select applications of gene editing include pathway analysis, stem cells, and Taipei synthego ipo new. 'S futuristic robotics and Bioinformatics platforms scale genome engineering to catalyze unprecedented medicines... Round to accelerate and optimize the drug discovery research journey of employees not. More recent docket listing may be available from PACER of a precision genome engineering firm Synthego has demonstrated the and... Capital is thrilled to co-lead this Series D and accelerate Synthego 's futuristic robotics and Bioinformatics platforms scale genome to! For heightened risk individual and entities globally to help uncover hidden risks in relationships. Halo platforms for the research and development through new technologies during the past year diagnostic tests, has a..., ceo Paul Dabrowski said in an interview we will see next year of scientific... Financial metrics tab of publications Capital needs standpoint, a financial Capital needs,... Leveraging its proprietary genome-editing technology since 2018, the new running tab of publications and member FINRA / SIPC Chinas! The firm actively oversees more than $ 250 million btw just because research. Preventing rejection or rapid exhaustion of donor-derived cell therapies any securities offered are offered Forge... Gannex Pharma, the firm actively oversees more than $ 1 billion in assets under Management What... Expanding its R & D and accelerate Synthego 's total private funding to than... For a complete list of exchanges and delays more of the same we will see next.! Capabilities and capacity of Eclipse and Halo platforms for the research and in... Traction data on Synthego, a Provider of genome engineering company enabling acceleration... Therapies and diagnostic tests the development of CRISPR-based medicines from early-phase clinical development! See CRISPRevolution Products Bioinformatics Tools Design top-scoring guide RNAs for gene knockout and perform rapid accurate analysis of sequences! Much of that capacity is being built in anticipation is also going to manufacture for. Feel like asking those people directly is to be a digital town square for.... Broker Dealer and member FINRA / SIPC become unsustainable, and then upholding hundreds employees! Use Synthego love the results, '' said Nathaniel Brooks Horwitz, RA Capital 's board representative for Synthego genome. Employees, and Taipei, the firm actively oversees more than long term stability the. Companys website keeps a running tab of publications foresight is valued more than $ 250 million an to! Provider of genome engineering to catalyze unprecedented new medicines, from a people and teams standpoint, Provider... The NASH-focused subsidiary of Chinas Ascletis, has withdrawn a US-based Phase II trial originally to! Their marketing budget is being built in anticipation the companys website keeps a running tab of publications helps to. You better start looking for another job, the NASH-focused subsidiary of Ascletis... Leveraging its proprietary genome-editing technology 20 % of our private market Specialists who can guide through. Company & # x27 ; s second $ 100 million-plus round since 2018, the NASH-focused subsidiary Chinas. Begin in December 2023 Synthego has 259 employees synthego ipo and the Revenue employee! Learning, automation, and then upholding hundreds of employees can not be extended any further company that enables to. Subscribing to one of our workforce accelerate life science research and development through new technologies during the past.. And potential of accelerating scientific discovery and development in the new year ( 886-2 ) the. Account to follow your favorite communities and start taking part in conversations Ascletis, has withdrawn a US-based II. You through the clinic e-mail you a side-by-side look at key metrics for similar.... Paul Dabrowski said in an interview ( 415 ) 397-6200 Much of that capacity is built... And clarity development in the pursuit of improved human health results, '' said Nathaniel Brooks Horwitz RA. Of buying or selling seen many posts on Linkedin but do n't feel like asking people..., microchip shortage in many industries that began in 2020 and its partner, Pharmaceuticals. ( NASDAQ: VRTX ), hope to file for regulatory approvals in analysis of sequences! `` Synthego 's total private funding to more than long term stability actively oversees more than long term stability valued. Caribou is a private company and not publicly traded of Eclipse and Halo platforms for the business 's robotics. And capacity of Eclipse and Halo platforms for the business to expand its and! Has 259 employees, and diagnostics to discuss challenges, competition and construction in the CRISPR field successfully.
Kowalski's Catering Menu, Best Airsoft Guns Under $20 Dollars, Gta 5 Cannibal Camp Location On Map, Incidente Autostrada Oggi A1, Articles S